Download
41416_2024_Article_2586.pdf 3,80MB
WeightNameValue
1000 Titel
  • Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
1000 Autor/in
  1. Baranyi, Marcell |
  2. Molnár, Eszter |
  3. Hegedűs, Luca |
  4. Gábriel, Zsófia |
  5. Petényi, Flóra Gréta |
  6. Bordás, Fanni |
  7. Léner, Violetta |
  8. Ranđelović, Ivan |
  9. Cserepes, Mihály |
  10. Tóvári, József |
  11. Hegedus, Balazs |
  12. Tímár, József |
1000 Verlag Nature Publishing Group UK
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-01-26
1000 Erschienen in
1000 Quellenangabe
  • 130(6):1059-1072
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41416-024-02586-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10951297/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Inhibition of mutant <jats:italic>KRAS</jats:italic> challenged cancer research for decades. Recently, allele-specific inhibitors were approved for the treatment of <jats:italic>KRAS-G12C</jats:italic> mutant lung cancer. However, de novo and acquired resistance limit their efficacy and several combinations are in clinical development. Our study shows the potential of combining G12C inhibitors with farnesyl-transferase inhibitors.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Combinations of clinically approved farnesyl-transferase inhibitors and KRAS G12C inhibitors are tested on human lung, colorectal and pancreatic adenocarcinoma cells in vitro in 2D, 3D and subcutaneous xenograft models of lung adenocarcinoma. Treatment effects on migration, proliferation, apoptosis, farnesylation and RAS signaling were measured by histopathological analyses, videomicroscopy, cell cycle analyses, immunoblot, immunofluorescence and RAS pulldown.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Combination of tipifarnib with sotorasib shows synergistic inhibitory effects on lung adenocarcinoma cells in vitro in 2D and 3D. Mechanistically, we present antiproliferative effect of the combination and interference with compensatory <jats:italic>HRAS</jats:italic> activation and <jats:italic>RHEB</jats:italic> and lamin farnesylation. Enhanced efficacy of sotorasib in combination with tipifarnib is recapitulated in the subcutaneous xenograft model of lung adenocarcinoma. Finally, combination of additional KRAS G1C and farnesyl-transferase inhibitors also shows synergism in lung, colorectal and pancreatic adenocarcinoma cellular models.</jats:p> </jats:sec><jats:sec> <jats:title>Discussion</jats:title> <jats:p>Our findings warrant the clinical exploration of <jats:italic>KRAS-G12C</jats:italic> inhibitors in combination with farnesyl-transferase inhibitors.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Adenocarcinoma of Lung [MeSH]
lokal Pancreatic Neoplasms/genetics [MeSH]
lokal Mutation [MeSH]
lokal Humans [MeSH]
lokal Lung Neoplasms/genetics [MeSH]
lokal Colorectal Neoplasms/drug therapy [MeSH]
lokal Animals [MeSH]
lokal Pancreatic Neoplasms/drug therapy [MeSH]
lokal /631/67/1612
lokal Proto-Oncogene Proteins p21(ras)/genetics [MeSH]
lokal Enzyme Inhibitors/pharmacology [MeSH]
lokal Article
lokal Adenocarcinoma/drug therapy [MeSH]
lokal Adenocarcinoma/genetics [MeSH]
lokal Transferases [MeSH]
lokal /631/67/1504
lokal Colorectal Neoplasms/genetics [MeSH]
lokal /631/67/1059
lokal Lung Neoplasms/drug therapy [MeSH]
lokal Disease Models, Animal [MeSH]
lokal article
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/QmFyYW55aSwgTWFyY2VsbA==|https://frl.publisso.de/adhoc/uri/TW9sbsOhciwgRXN6dGVy|https://frl.publisso.de/adhoc/uri/SGVnZWTFsXMsIEx1Y2E=|https://frl.publisso.de/adhoc/uri/R8OhYnJpZWwsIFpzw7NmaWE=|https://frl.publisso.de/adhoc/uri/UGV0w6lueWksIEZsw7NyYSBHcsOpdGE=|https://frl.publisso.de/adhoc/uri/Qm9yZMOhcywgRmFubmk=|https://frl.publisso.de/adhoc/uri/TMOpbmVyLCBWaW9sZXR0YQ==|https://frl.publisso.de/adhoc/uri/UmFuxJFlbG92acSHLCBJdmFu|https://frl.publisso.de/adhoc/uri/Q3NlcmVwZXMsIE1paMOhbHk=|https://frl.publisso.de/adhoc/uri/VMOzdsOhcmksIErDs3pzZWY=|https://orcid.org/0000-0002-4341-4153|https://frl.publisso.de/adhoc/uri/VMOtbcOhciwgSsOzenNlZg==
1000 Hinweis
  • DeepGreen-ID: 0033922c40544799a743eda34e7211b4 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6518913.rdf
1000 Erstellt am 2025-07-05T14:23:31.920+0200
1000 Erstellt von 322
1000 beschreibt frl:6518913
1000 Zuletzt bearbeitet 2025-08-15T21:12:53.667+0200
1000 Objekt bearb. Fri Aug 15 21:12:53 CEST 2025
1000 Vgl. frl:6518913
1000 Oai Id
  1. oai:frl.publisso.de:frl:6518913 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source